


Status: Currently Official on 16-Feb-2025  
 Official Date: Official as of 01-May-2020  
 Document Type: USP Monographs  
 DocId: GUID-CC8413FB-9C1A-4E27-9E7B-B942BD1AF781\_2\_en-US  
 DOI: [https://doi.org/10.31003/USPNF\\_M69710\\_02\\_01](https://doi.org/10.31003/USPNF_M69710_02_01)  
 DOI Ref: cz3hj

© 2025 USPC  
 Do not distribute

## Prochlorperazine Maleate



$C_{20}H_{24}ClN_3S \cdot 2C_4H_4O_4$  606.09

10*H*-Phenothiazine, 2-chloro-10-[3-(4-methyl-1-piperazinyl)propyl]-, (Z)-2-butenedioate (1:2);

2-Chloro-10-[3-(4-methylpiperazin-1-yl)propyl]phenothiazine maleate (1:2) CAS RN®: 84-02-6; UNII: 11T8O1JTL6.

### DEFINITION

Prochlorperazine Maleate contains NLT 98.0% and NMT 102.0% of prochlorperazine maleate ( $C_{20}H_{24}ClN_3S \cdot 2C_4H_4O_4$ ), calculated on the dried basis.

[NOTE—Throughout the following procedures, protect the samples, the Reference Standard, and solutions containing them from light, and conduct the procedures without delay.]

### IDENTIFICATION

#### Change to read:

- **A.** ▲ **SPECTROSCOPIC IDENTIFICATION TESTS (197), Infrared Spectroscopy:** 197A or 197K. ▲ (CN 1-May-2020)
- **B.** The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.

### ASSAY

#### PROCEDURE

**Ion-pairing solution:** Dissolve 4.33 g of [sodium 1-octanesulfonate](#) in 500 mL of [water](#). Add 4.0 mL of [glacial acetic acid](#), and dilute with [water](#) to 1 L.

**Mobile phase:** [Acetonitrile](#), [methanol](#), and *Ion-pairing solution* (40:15:45)

**Standard solution:** 0.2 mg/mL of [USP Prochlorperazine Maleate RS](#) in *Mobile phase*. Sonicate to dissolve, if needed, prior to final dilution.

**Sample solution:** 0.2 mg/mL of Prochlorperazine Maleate in *Mobile phase*. Sonicate to dissolve, if needed, prior to final dilution.

#### Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

**Mode:** LC

**Detector:** UV 254 nm

**Column:** 3.9-mm × 30-cm; 10-μm packing L1 or 4.6-mm × 25-cm; 5-μm packing L1

**Flow rate:** 2 mL/min

**Injection volume:** 10 μL

#### System suitability

**Sample:** *Standard solution*

#### Suitability requirements

**Tailing factor:** NMT 2.0

**Relative standard deviation:** NMT 0.73%

#### Analysis

**Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of prochlorperazine maleate ( $C_{20}H_{24}ClN_3S \cdot 2C_4H_4O_4$ ) in the portion of Prochlorperazine Maleate taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

$r_U$  = peak response of prochlorperazine from the *Sample solution*

$r_S$  = peak response of prochlorperazine from the *Standard solution*

$C_S$  = concentration of [USP Prochlorperazine Maleate RS](#) in the *Standard solution* (mg/mL)

$C_U$  = concentration of Prochlorperazine Maleate in the *Sample solution* (mg/mL)

**Acceptance criteria:** 98.0%–102.0% on the dried basis

#### IMPURITIES

• [RESIDUE ON IGNITION \(281\)](#): NMT 0.1%

#### • ORGANIC IMPURITIES

**Buffer:** 1.36 g/L of [sodium acetate](#) trihydrate in water (0.01 M). Add 2.0 mL of [triethylamine](#) and 6.0 mL of [glacial acetic acid](#) per L of solution.

**Solution A:** *Buffer*

**Solution B:** [Acetonitrile](#)

**Mobile phase:** See [Table 1](#). Return to original conditions, and re-equilibrate the system for about 10 min.

**Table 1**

| Time<br>(min) | Solution A<br>(%) | Solution B<br>(%) |
|---------------|-------------------|-------------------|
| 0             | 75                | 25                |
| 20            | 65                | 35                |
| 25            | 65                | 35                |
| 55            | 35                | 65                |
| 65            | 35                | 65                |

**Diluent:** Acetonitrile and water (40:60)

**Impurity stock solution:** 0.16 mg/mL of [USP Prochlorperazine Related Compound A RS](#) in *Diluent*

**Standard stock solution:** 0.16 mg/mL of [USP Prochlorperazine Maleate RS](#) in *Diluent*

**System suitability solution:** 1.6 µg/mL each of [USP Prochlorperazine Maleate RS](#) and [USP Prochlorperazine Related Compound A RS](#) in *Diluent* from the *Standard stock solution* and the *Impurity stock solution*, respectively

**Standard solution:** 6.4 µg/mL of [USP Prochlorperazine Maleate RS](#) in *Diluent* from the *Standard stock solution*

**Sensitivity solution:** 0.32 µg/mL of [USP Prochlorperazine Maleate RS](#) in *Diluent* from the *Standard solution*

**Sample solution:** 0.64 mg/mL of Prochlorperazine Maleate in *Diluent*

#### Chromatographic system

(See [Chromatography \(621\). System Suitability](#).)

**Mode:** LC

**Detector:** UV 254 nm

**Column:** 4.6-mm × 25-cm; 5-µm packing L1

**Column temperature:** 50 ± 5°

**Flow rate:** 2.0 mL/min

**Injection volume:** 20 µL

#### System suitability

**Samples:** *System suitability solution*, *Standard solution*, and *Sensitivity solution*

#### Suitability requirements

**Resolution:** NLT 2.0 between prochlorperazine related compound A and prochlorperazine, *System suitability solution*

**Relative standard deviation:** NMT 5.0%, *Standard solution*

**Signal-to-noise ratio:** NLT 10, *Sensitivity solution*

#### Analysis

**Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of each individual impurity in the portion of Prochlorperazine Maleate taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times (M_{r1}/M_{r2}) \times (1/F) \times 100$$

$r_U$  = peak response of each impurity from the *Sample solution*

$r_S$  = peak response of prochlorperazine from the *Standard solution*

$C_S$  = concentration of [USP Prochlorperazine Maleate RS](#) in the *Standard solution* (mg/mL)

$C_U$  = concentration of Prochlorperazine Maleate in the *Sample solution* (mg/mL)

$M_{r1}$  = molecular weight of prochlorperazine, 373.94

$M_{r2}$  = molecular weight of prochlorperazine maleate, 606.09

$F$  = relative response factor (see [Table 2](#))

**Acceptance criteria:** See [Table 2](#). Disregard any peak below 0.05%.

**Table 2**

| Name                                                                                | Relative Retention Time | Relative Response Factor <sup>a</sup> | Acceptance Criteria, NMT (%) |
|-------------------------------------------------------------------------------------|-------------------------|---------------------------------------|------------------------------|
| Maleic acid                                                                         | 0.07                    | —                                     | Disregard                    |
| Prochlorperazine sulfoxide <sup>b</sup>                                             | 0.20                    | 0.38                                  | 0.15                         |
| Perazine <sup>c</sup>                                                               | 0.66                    | 1.0                                   | 0.15                         |
| Prochlorperazine 4-chloro isomer (prochlorperazine related compound A) <sup>d</sup> | 0.97                    | 0.61                                  | 0.15                         |
| Prochlorperazine                                                                    | 1.00                    | —                                     | —                            |
| 4-Chlorophenothiazine <sup>e</sup>                                                  | 2.01                    | 1.9                                   | 0.1                          |
| 2-Chlorophenothiazine <sup>f</sup>                                                  | 2.08                    | 2.1                                   | 0.1                          |
| Specified unknown 1                                                                 | 2.64                    | 1.0                                   | 0.50                         |
| Specified unknown 2                                                                 | 2.79                    | 1.0                                   | 0.50                         |
| Specified unknown 3                                                                 | 2.88                    | 1.0                                   | 0.20                         |
| Any other individual impurity                                                       | —                       | 1.0                                   | 0.10                         |
| Total impurities                                                                    | —                       | —                                     | 1.5                          |

<sup>a</sup>  $F$  values are based on the response of prochlorperazine (free base).

<sup>b</sup> 2-Chloro-10-[3-(4-methylpiperazin-1-yl)propyl]-10*H*-phenothiazine sulfoxide.

<sup>c</sup> 10-[3-(4-Methylpiperazin-1-yl)propyl]-10*H*-phenothiazine.

<sup>d</sup> 4-Chloro-10-[3-(4-methylpiperazin-1-yl)propyl]-10*H*-phenothiazine.

<sup>e</sup> 4-Chloro-10*H*-phenothiazine.

<sup>f</sup> 2-Chloro-10*H*-phenothiazine.

SPECIFIC TESTS

- [Loss on Drying \(731\)](#)

**Analysis:** Dry under vacuum at 60° for 2 h.

**Acceptance criteria:** NMT 0.5%

ADDITIONAL REQUIREMENTS


- **PACKAGING AND STORAGE:** Preserve in tight, light-resistant containers. Store at room temperature.

- [USP REFERENCE STANDARDS \(11\)](#)

[USP Prochlorperazine Maleate RS](#)

[USP Prochlorperazine Related Compound A RS](#)

4-Chloro-10-[3-(4-methylpiperazin-1-yl)propyl]-10H-phenothiazine dihydrochloride.



**Auxiliary Information** - Please [check for your question in the FAQs](#) before contacting USP.

| Topic/Question             | Contact                                                                     | Expert Committee          |
|----------------------------|-----------------------------------------------------------------------------|---------------------------|
| PROCHLORPERAZINE MALEATE   | <a href="#">Documentary Standards Support</a>                               | SM32020 Small Molecules 3 |
| REFERENCE STANDARD SUPPORT | RS Technical Services<br><a href="mailto:RSTECH@usp.org">RSTECH@usp.org</a> | SM32020 Small Molecules 3 |

**Chromatographic Database Information:** [Chromatographic Database](#)

**Most Recently Appeared In:**

Pharmacopeial Forum: Volume No. PF 42(1)

**Current DocID:** GUID-CC8413FB-9C1A-4E27-9E7B-B942BD1AF781\_2\_en-US

**DOI:** [https://doi.org/10.31003/USPNF\\_M69710\\_02\\_01](https://doi.org/10.31003/USPNF_M69710_02_01)

**DOI ref:** [cz3hj](#)